Pembrolizumab in Locally Advanced Sinonasal Carcinoma

NCT05925491 | Recruiting Phase 2 FDA Drug

• 1 other identifier: NeoPeSino
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC). Activity of neoadjuvant chemotherapy in locally advanced SNUC has been already demonstrated; the primary hypothesis is that the addition of pembrolizumab as neoadjuvant and adjuvant agent might confirm the results obtained with a combined treatment strategy including chemotherapy, decreasing the burden of treatment-related side effects.

Conditions

Sinonasal Undifferentiated Carcinoma

Keywords

Sinonasal Undifferentiated Carcinoma; SNUC; neoadjuvant immunotherapy; neoadjuvant treatment; locally advanced; pembrolizumab; neoadjuvant

Outcome Measures

Primary Outcomes (1)

• Neoadjuvant therapy objective response rate (ORR)

  ORR defined as the sum of complete remission (CRs) and partial responses (PRs) by RECIST v. 1.1

  Up to 24 months after the end of neoadjuvant treatment

Study Arms (1)

Neoadjuvant Pembrolizumab

EXPERIMENTAL

Patients will receive pembrolizumab 200 mg + cisplatin 75mg/mq (or Carboplatin AUC 5) and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses, followed by standard of care.

Drug: Pembrolizumab; Drug: Cisplatin; Drug: Docetaxel; Drug: Carboplatin

Interventions

Pembrolizumab DRUG

Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care

Neoadjuvant Pembrolizumab

Cisplatin DRUG

Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.

Neoadjuvant Pembrolizumab

Docetaxel DRUG

Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.

Neoadjuvant Pembrolizumab

Carboplatin DRUG

Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.

Neoadjuvant Pembrolizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have centrally histologically-confirmed, treatment-naïve SNUC that is considered curable by local therapies.
• Have locally advanced disease defined as stage III of IV a-b according to American Joint Committee on Cancer (AJCC) cancer staging system VIII edition.
• Be willing and able to provide written informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
• Be ≥ 18 years of age on day of signing informed consent.
• Have measurable disease based on RECIST 1.1 as determined by the site.
• Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
• Demonstrate adequate organ function.
• A male participant must agree to use contraception during the treatment period and for at least 180 days after last dose, corresponding to time needed to eliminate any study treatments plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity. He must refrain from donating sperm during this period, too.
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
• o Not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees use contraception during the treatment period and for at least 180 days (corresponding to time needed to eliminate any study treatments plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment.
• Have provided tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred.

You may not qualify if:

• Participants are excluded from the study if any of the following criteria apply:
• Has disease that is deemed not suitable for local therapy administered with curative intent (e.g. severe brain involvement).
• \. Have metastatic disease defined as stage IV c according to AJCC cancer staging system VIII edition.
• A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
• Has received prior systemic anti-cancer therapy including investigational agents prior to allocation.
• Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Administration of killed vaccines is allowed.
• Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
• Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in-situ (eg, breast carcinoma or cervical cancer in situ that have undergone potentially curative therapy are not excluded
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.
• Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
• Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• Has an active infection requiring systemic therapy.

Sponsors & Collaborators

• Istituti Clinici Scientifici Maugeri SpA: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

Istituti Clinici Scientifici Maugeri

Pavia, Lombardy, 27100, Italy

RECRUITING

MeSH Terms

Conditions

Sinonasal undifferentiated carcinoma

Interventions

pembrolizumab; Cisplatin; Docetaxel; Carboplatin

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Coordination Complexes

Study Officials

• Laura D Locati, MD, PhD

  Istituti Clinici Scientifici Maugeri

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Serena Barbaro, M.Sc.

CONTACT

+39 (0)3982592326; CTCstaff.pavia@icsmaugeri.it

Laura D Locati, MD, PhD

CONTACT

0382592326; lauradeborahlocati@icsmaugeri.it

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 21, 2023
• First Posted: June 29, 2023
• Study Start: December 24, 2024
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027
• Last Updated: April 16, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)